DexCom, Inc.
Key Metrics
- Previous Close
- $89.88
- 52-Week Range
- $54.11 – $91.96
- Market Cap
- $34.05B
- P/E (TTM)
- 35.52
- EPS (TTM)
- 2.54
- Dividend Yield
- —
Advanced Metrics
- Price/Book
- 12.99
- PEG Ratio
- 1.70
- Return on Equity
- 38.49%
- Return on Assets
- 10.33%
- Gross Margin
- 62.47%
- Operating Margin
- 24.33%
- Profit Margin
- 20.12%
- Current Ratio
- 1.73
- Debt/Equity
- 0.53
- Total Debt
- $1.40B
- Free Cash Flow
- $1.02B
- Revenue Growth
- 13.10%
- Earnings Growth
- 43.60%
- Enterprise Value
- $33.50B
Market Snapshot
About
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. The company's flagship products, including the Dexcom G6 and G7 systems, provide real-time glucose readings without the need for fingerstick calibration. DexCom's CGM technology uses a small sensor inserted under the skin that transmits glucose data wirelessly to a receiver or smartphone app. The company's systems help patients manage their diabetes more effectively and reduce the risk of dangerous blood sugar fluctuations. DexCom serves both Type 1 and Type 2 diabetes patients and has partnerships with insulin pump manufacturers for integrated diabetes management systems.